NS
TSHA icon

NBC Securities’s Taysha Gene Therapies TSHA Stock Holding History

NBC Securities’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Buy
55,022
+964
+2% +$5.71K 0.03% 637
2026
Q1 		$242K Buy
54,058
+1,103
+2% +$5.13K 0.02% 779
2025
Q4 		$291K Buy
+52,955
New +$257K 0.02% 697

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NBC Securities's TSHA Position: Q2 2026 in Review

NBC Securities increased its Taysha Gene Therapies (TSHA) stake by 1.8% in Q2 2026, buying an estimated $5.71K and bringing the position to 55,022 shares worth $375K. The position accounts for 0.03% of the portfolio, ranked #637.

NBC Securities first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • NBC Securities held 55,022 shares of Taysha Gene Therapies worth $375K as of Q2 2026.
  • NBC Securities bought 964 Taysha Gene Therapies shares in Q2 2026, an estimated $5.71K.
  • Taysha Gene Therapies made up 0.03% of NBC Securities's portfolio in Q2 2026, its #637 holding.
  • NBC Securities first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.